The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment

Hadya Elshakh, Khalid El-Ejji, Shahrad Taheri

Research output: Contribution to journalReview article

4 Citations (Scopus)


Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.

Original languageEnglish
Pages (from-to)2471-2478
Number of pages8
JournalObesity Surgery
Issue number9
Publication statusPublished - 1 Sep 2017



  • Botulinum toxin-A
  • Endoscopy
  • Obesity

ASJC Scopus subject areas

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this